ThymuskinANZ is the supplier of Thymuskin product range in Australia and New Zealand.
Vita-Cos-Med Klett-Loch GmbH manufactures Thymuskin products in Germany.
For more than 30 years, Vita-Cos-Med Klett-Loch GmbH has been successfully engaged in research, development and distribution of healthcare products with biologically active thymic peptide agents. The patented thymic peptide libraries GKL-02/03 are a mimicry of the natural thymic total extract and worldwide unique.
Thymic therapies are used successful in medical practice since decades. Now, the active ingredients GKL-02/03 allow the application of thymic therapies – without the use of ingredients of animal origin.
In-company research in the pharmaceutical and cosmetic field started in 1976, and in 1981 the company was able to demonstrate the unique effectiveness of the low molecular thymus hydrolysate GKL-01 in treating androgenetic hair loss.
Since then the brand Thymuskin is regarded as one of the leading preparations worldwide for counteracting hair loss and encouraging the formation of new hair. Further pharmaceutical innovations such as the development of the bovine-free low molecular, statistical thymic peptide library GKL-02 and numerous other pharmaceutical patents and products have followed.
In 2005 Thymuskin SCLERO discret was introduced, for the treatment of the skin of the intimate area, escpecially to treat Lichen sclerosus. During a clinical observational study, an improvement up to complete freedom of symptoms could be confirmed in 80% of all cases (M. Loehnert, S. Rappich, M. Hagedorn: Treatment and care of lichen sclerosus, Sept. 2005). The preparation is also positively mentioned in the well noted Encyclopedia of Dermatology, Allergy, Environmental medicine, Altmeyer & Paech 2010: "Analog good results, compared to the calcineurin inhibitors, were made with the approach using a thymic peptide active agent".
Another major success was the introduction of Thymrevit Revitalizing Capsules in 2008. This dietary supplement for special medical purposes has helped many people since in the treatment of diseases associated with immune disorders and immune weakness. Right from the beginning we have supported the technology transfer of biochemical innovations in close cooperation with universities and teaching hospitals.
GKL BIOTEC AG
a subsidiary of the company group Klett-Loch
Based on 25 years of continuous and intensive research on active pharmaceutical ingredients (API’s) in the field of Thymus Peptides, the company GKL-BIOTEC-AG was founded in January 2008. We focus on the development of GKL thymic peptide ingredient complexes for the pharmaceutical and cosmetics industry. In close cooperation with renowned universities we promote the technological transfer of biochemical innovations. The existing results have underlined the success of our approach.
Within the Pharmaceutical Industry our GKL thymic peptide ingredient complexes are suitable for the production of medical products in the sectors of Immunology, Oncology and Dermatology, as well as further therapeutic fields, such as Rheumatic Diseases.
In the sector of dermatology our GKL thymic peptide ingredient complexes are suitable for the use in preparations against the different types and causes of hair loss and for the stimulation of new hair growth. Furthermore they are suitable for preparations against skin diseases, such as Lichen Sclerosis and particularly for preparations against the different characteristics linked with the ageing process of the skin.